Parathyroid hormone type 1 receptor regulates osteosarcoma K7M2 Cell growth by interacting with angiotensinogen
暂无分享,去创建一个
[1] Robin L. Jones,et al. Future Directions in the Treatment of Osteosarcoma , 2021, Cells.
[2] Shenglong Li,et al. Long noncoding RNA LINC01278 favors the progression of osteosarcoma via modulating miR-133a-3p/PTHR1 signaling. , 2020, Journal of cellular physiology.
[3] Wen-Zhe Yin,et al. Mangiferin suppresses human metastatic osteosarcoma cell growth by down-regulating the expression of metalloproteinases-1/2 and parathyroid hormone receptor 1 , 2020, AMB Express.
[4] Shenglong Li,et al. PTHR1 May Be Involved in Progression of Osteosarcoma by Regulating miR-124-3p-AR-Tgfb1i1, miR-27a-3p-PPARG-Abca1, and miR-103/590-3p-AXIN2 Axes. , 2019, DNA and cell biology.
[5] Tomoyuki Watanabe,et al. Structure and dynamics of the active human parathyroid hormone receptor-1 , 2019, Science.
[6] V. Gaponenko,et al. Novel peptide nanoparticle–biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness , 2019, The Journal of allergy and clinical immunology.
[7] Jianbo Jia,et al. miR‐21 and miR‐19b delivered by hMSC‐derived EVs regulate the apoptosis and differentiation of neurons in patients with spinal cord injury , 2018, Journal of cellular physiology.
[8] B. Uhal,et al. Local activation of the pulmonary extravascular angiotensin system induces epithelial apoptosis and lung fibrosis. , 2018, Journal of lung, pulmonary & respiratory research.
[9] Minghua Li,et al. AngII induces HepG2 cells to activate epithelial-mesenchymal transition , 2018, Experimental and therapeutic medicine.
[10] B. Zhu,et al. Silencing of ENO1 by shRNA Inhibits the Proliferation of Gastric Cancer Cells , 2018, Technology in cancer research & treatment.
[11] Shenglong Li,et al. β-Alanine mediated inhibition of PTHR1suppresses the proliferation, invasion and tumorigenesis in metastatic human osteosarcoma U2OS cells. , 2018, International journal of biological macromolecules.
[12] A. Huber,et al. An emerging role for eotaxins in neurodegenerative disease. , 2016, Clinical immunology.
[13] G. Evan,et al. Myc Cooperates with Ras by Programming Inflammation and Immune Suppression , 2017, Cell.
[14] Ke Wang,et al. Transcriptomic analyses reveal the underlying pro-malignant functions of PTHR1 for osteosarcoma via activation of Wnt and angiogenesis pathways , 2017, Journal of Orthopaedic Surgery and Research.
[15] Jianlin Zhou,et al. High CCL5 expression is associated with osteosarcoma metastasis and poor prognosis of patients with osteosarcoma. , 2017, Molecular medicine reports.
[16] Hongyan Lu,et al. Overexpression of AGT promotes bronchopulmonary dysplasis via the JAK/STAT signal pathway , 2017, Oncotarget.
[17] Jinlong Li,et al. Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer , 2017, Journal of experimental & clinical cancer research : CR.
[18] M. Cui,et al. MicroRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer. , 2017, American journal of translational research.
[19] S. Russell,et al. Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart , 2016, European journal of immunology.
[20] D. Spandidos,et al. Parathyroid hormone/parathyroid hormone-related peptide regulate osteosarcoma cell functions: Focus on the extracellular matrix (Review) , 2016, Oncology reports.
[21] K. Matsuo,et al. Efficient Use of a Crude Drug/Herb Library Reveals Ephedra Herb As a Specific Antagonist for TH2-Specific Chemokine Receptors CCR3, CCR4, and CCR8 , 2016, Front. Cell Dev. Biol..
[22] Min Tian,et al. Expression and prognostic significance of CCL11/CCR3 in glioblastoma , 2016, Oncotarget.
[23] K. Janeway,et al. Future directions in the treatment of osteosarcoma , 2016, Current opinion in pediatrics.
[24] K. Hunter,et al. CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. , 2015, Cancer research.
[25] P. Meltzer,et al. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] T. Martin,et al. PTHrP, its receptor, and protein kinase A activation in osteosarcoma , 2014, Molecular & cellular oncology.
[27] A. Chalk,et al. Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo , 2014, Oncogene.
[28] Jilong Yang,et al. Advances in targeted therapy for osteosarcoma. , 2014, Discovery medicine.
[29] Zhousheng Xiao,et al. Downregulation of PKD1 by shRNA results in defective osteogenic differentiation via cAMP/PKA pathway in human MG‐63 cells , 2012, Journal of cellular biochemistry.
[30] James J. Lee,et al. CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling. , 2011, American Journal of Pathology.
[31] S. Schulz,et al. Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. , 2010, European journal of endocrinology.
[32] P. Corvol,et al. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. , 2009, Cancer research.
[33] M. Alokail,et al. Quantitative comparison of PTH1R in breast cancer MCF7 and osteosarcoma SaOS‐2 cell lines , 2008, Cell biochemistry and function.
[34] A. Huvos,et al. Over‐expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma , 2007, International journal of cancer.
[35] P. Opolon,et al. Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] J. Egido,et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[37] W. Hsueh,et al. Angiotensin II in cell growth and matrix production. , 1995, Advances in experimental medicine and biology.